{"id":"NCT01294384","sponsor":"Allergan","briefTitle":"Safety and Efficacy Study of New Eye Drop Formulations With Refresh Tears® in Patients With Dry Eye Disease","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05-01","primaryCompletion":"2012-09-25","completion":"2012-09-25","firstPosted":"2011-02-11","resultsPosted":"2013-11-25","lastUpdate":"2019-04-16"},"enrollment":305,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndromes"],"interventions":[{"type":"DRUG","name":"carboxymethylcellulose sodium based New Eye Drop Formulation 1","otherNames":[]},{"type":"DRUG","name":"carboxymethylcellulose sodium based New Eye Drop Formulation 2","otherNames":[]},{"type":"DRUG","name":"carboxymethylcellulose sodium based Eye Drops","otherNames":["Refresh Tears®"]}],"arms":[{"label":"New Eye Drop Formulation 1","type":"EXPERIMENTAL"},{"label":"New Eye Drop Formulation 2","type":"EXPERIMENTAL"},{"label":"Refresh Tears®","type":"ACTIVE_COMPARATOR"}],"summary":"This study will investigate the safety, efficacy and acceptability of two new eye drop formulations compared with Refresh Tears® in patients with dry eye disease.","primaryOutcome":{"measure":"Change From Baseline in Ocular Surface Disease Index© (OSDI) Score","timeFrame":"Baseline, Day 90","effectByArm":[{"arm":"New Eye Drop Formulation 1","deltaMin":36.83,"sd":13.35},{"arm":"New Eye Drop Formulation 2","deltaMin":38.51,"sd":12.512},{"arm":"Refresh Tears®","deltaMin":38.86,"sd":11.88}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":2,"countries":["Australia","Canada"]},"refs":{"pmids":["25931807"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":102},"commonTop":[]}}